Radiotherapy as the primary approach in the treatment of laryngeal cancer.

Canadian journal of otolaryngology Pub Date : 1975-01-01
I Jankovic, Z Merkas
{"title":"Radiotherapy as the primary approach in the treatment of laryngeal cancer.","authors":"I Jankovic,&nbsp;Z Merkas","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>At the Institute of Radiology, University of Belgrade, in close collaboration with ENT Hospital, a group of 772 patients were treated at various stages of laryngeal cancer with telecobalt therapy during the 1960-68 period. The supervoltage was consistently the primary approach in the treatment with curative intent, while surgery was resorted to for the failures only. One hundred and thirteen patients with recurrences following their exposure to irradiation, unfit for an operation or refusing surgery, were re-irradiated with telecobalt therapy. The authors studied several overall time, dose and fractionation schemes. The NSD concept of Ellis was employed to compare the biological effects of the different treatment factors. The optimum results were obtained with the doses fractioned over five or six weeks and NSD amounting to 1950. The five year absolute survival rate obtained at glottic cancer was 60.9 per cent. All stages of supraglottic cancer had a survival rate of 39.2 per cent. The five year survival after the second course of irradiation (113 patients) was 22.1 per cent, including 25 patients operated on after two series of irradiation. The authors consider that the risk of a radical re-irradiation has to be accepted in spite of possible complications because it is the only possibility to save a limited number of the patients unfit for an operation or who have a negative attitude to surgical treatment, especially to laryngectomy.</p>","PeriodicalId":75670,"journal":{"name":"Canadian journal of otolaryngology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1975-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian journal of otolaryngology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

At the Institute of Radiology, University of Belgrade, in close collaboration with ENT Hospital, a group of 772 patients were treated at various stages of laryngeal cancer with telecobalt therapy during the 1960-68 period. The supervoltage was consistently the primary approach in the treatment with curative intent, while surgery was resorted to for the failures only. One hundred and thirteen patients with recurrences following their exposure to irradiation, unfit for an operation or refusing surgery, were re-irradiated with telecobalt therapy. The authors studied several overall time, dose and fractionation schemes. The NSD concept of Ellis was employed to compare the biological effects of the different treatment factors. The optimum results were obtained with the doses fractioned over five or six weeks and NSD amounting to 1950. The five year absolute survival rate obtained at glottic cancer was 60.9 per cent. All stages of supraglottic cancer had a survival rate of 39.2 per cent. The five year survival after the second course of irradiation (113 patients) was 22.1 per cent, including 25 patients operated on after two series of irradiation. The authors consider that the risk of a radical re-irradiation has to be accepted in spite of possible complications because it is the only possibility to save a limited number of the patients unfit for an operation or who have a negative attitude to surgical treatment, especially to laryngectomy.

放疗是喉癌治疗的主要途径。
1960- 1968年期间,贝尔格莱德大学放射研究所与耳鼻喉科医院密切合作,对772名不同阶段的喉癌患者进行了远程钴疗法治疗。高压治疗一直是治疗目的的主要方法,而手术仅用于治疗失败。113例放疗后复发、不适合手术或拒绝手术的患者再次接受远程钴治疗。作者研究了几种总的时间、剂量和分离方案。采用Ellis的NSD概念比较不同治疗因素的生物学效应。最佳的结果是在5或6周的时间内,NSD为1950。声门癌的5年绝对生存率为60.9%。所有阶段的声门上癌的生存率为39.2%。第二次放射治疗后的5年生存率(113例)为22.1%,其中25例患者在两次放射治疗后手术。作者认为,尽管可能出现并发症,但必须接受根治性再照射的风险,因为这是拯救有限数量不适合手术或对手术治疗,特别是对喉切除术持消极态度的患者的唯一可能性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信